PreciseDx said it plans to use the investment to advance its AI for breast cancer diagnostics and risk assessment. The startup, which has brought in $31.5 million to date, has also started collaborating with Los Angeles-based UCLA Health, Coral Gables, Fla.-based Baptist Health, and Dallas-based Baylor Scott & White Health.
“Our team continues to advance breast cancer diagnostics by delivering faster, more accurate data, in a cost-efficient method,” said Eric Converse, founding board member of PreciseDx, in an Aug. 21 statement. “This allows clinical care teams to make better informed clinical decisions resulting in improved patient outcomes.”
The funding round was led by biotech investor Eventide Asset Management and also included laboratory giants Labcorp and Quest Diagnostics.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
